Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

<p>The most recent American Diabetes Association 2018 guidelines suggest that for persons with established cardiovascular disease who have not attained glucose goals, incorporation of agents that have shown cardiovascular risk reduction (i.e., canagliflozin, empagliflozin, liraglutide) should be a priority.</p>

Postprandial Glucose Excursions in Type 2 Diabetes